Form 4: C4 Therapeutics Director Stephen Fawell Acquires 65,000 Stock Options

Director Stephen Fawell acquired 65,000 stock options in C4 Therapeutics, Inc. on August 29, 2024.

Summary

• Stephen Fawell, a director of C4 Therapeutics, Inc. [CCCC], acquired 65,000 stock options on August 29, 2024.
• The exercise price of these options is $6.43.
• The options vest over time, with 33% vesting on August 29, 2025, and the remainder vesting in equal quarterly installments thereafter, contingent upon continued service.
• The options expire on August 28, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It reflects a routine transaction (stock option grant) to a director, which is generally viewed as a sign of alignment between management and shareholders.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the options (33% on August 29, 2025, and the remainder in equal quarterly installments) suggests a long-term commitment from the director.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a director's investment in the company's stock, which is common practice.

Stakeholder Impact

• The acquisition of stock options by a director could positively influence shareholder sentiment.

Key Dates